FR2085735A1 - - Google Patents

Info

Publication number
FR2085735A1
FR2085735A1 FR7110328A FR7110328A FR2085735A1 FR 2085735 A1 FR2085735 A1 FR 2085735A1 FR 7110328 A FR7110328 A FR 7110328A FR 7110328 A FR7110328 A FR 7110328A FR 2085735 A1 FR2085735 A1 FR 2085735A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7110328A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of FR2085735A1 publication Critical patent/FR2085735A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7110328A 1970-03-24 1971-03-24 Withdrawn FR2085735A1 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1436570 1970-03-24
GB3643070 1970-07-28

Publications (1)

Publication Number Publication Date
FR2085735A1 true FR2085735A1 (enExample) 1971-12-31

Family

ID=26250514

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7110328A Withdrawn FR2085735A1 (enExample) 1970-03-24 1971-03-24

Country Status (5)

Country Link
US (1) US3787581A (enExample)
AU (1) AU2682871A (enExample)
BE (1) BE764768A (enExample)
DE (1) DE2113994A1 (enExample)
FR (1) FR2085735A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287341A1 (en) * 1987-04-17 1988-10-19 Merck & Co. Inc. Rectally absorbable form of L-dopa
EP0252290A3 (en) * 1986-06-10 1990-01-24 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801624A (en) * 1970-12-09 1974-04-02 Aldrich Chem Co Inc Di-substituted beta-phenethylcarbamic acid esters
US4117161A (en) * 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0252290A3 (en) * 1986-06-10 1990-01-24 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
EP0287341A1 (en) * 1987-04-17 1988-10-19 Merck & Co. Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
AU2682871A (en) 1972-09-28
DE2113994A1 (de) 1971-10-14
US3787581A (en) 1974-01-22
BE764768A (fr) 1971-09-24

Similar Documents

Publication Publication Date Title
AR204384A1 (enExample)
FR2117953A1 (enExample)
ATA96471A (enExample)
AU2044470A (enExample)
AU1146470A (enExample)
AU1473870A (enExample)
AU1326870A (enExample)
AU2017870A (enExample)
AU2085370A (enExample)
AU2130570A (enExample)
AU1833270A (enExample)
AU1716970A (enExample)
AU1517670A (enExample)
AU1336970A (enExample)
AU1235770A (enExample)
AU1841070A (enExample)
AU1277070A (enExample)
AU1328670A (enExample)
AU1247570A (enExample)
AU1343870A (enExample)
AU1943370A (enExample)
AU2144270A (enExample)
AU1189670A (enExample)
AU1581370A (enExample)
AU1591370A (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse